
    
      In Part I, patients who have had prior AZT therapy receive either nevirapine or placebo in
      combination with AZT. In Part II, patients who are nucleoside naive receive either nevirapine
      or matching placebo. After 6 months, patients receive open-label nevirapine.
    
  